Correlation of pharmacokinetic dispositionof methotrexate and serum cytokine levels in rheumatoid arthritis patients

Authors

  • Raisa Aringazina Department of Internal Diseases № 1, Non-Commercial joint-stock Society “West Kazakhstan Marat Ospanov Medical University”, Aktobe, Kazakhstan
  • Leysan Myasoutova Department of Hospital Therapy, Kazan State Medical University, Kazan, Russian Federation
  • Liudmila Babaskina Department of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • Olga Pashanova Department of Economics and Organization of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation

DOI:

https://doi.org/10.3329/bjms.v21i2.58066

Keywords:

clinical markers of inflammation; cytokine profile; methotrexate in rheumatoid arthritis; pharmacokinetics of methotrexate; rheumatoid arthritis

Abstract

Objective: Methotrexate is the principal basic anti-inflammatory medication used in the rheumatoid arthritis treatment.Therefore, research into its effect on cytokine concentrations may help improve the effectiveness of disease treatment.

Study aim: was to investigate the neffect of methotrexate therapy on the blood content of proinflammatory cytokines in RA patients, as well as define the relation of proinflammatory cytokine blood concentration to clinical and laboratory disease features and methotrexate pharmacokinetics.

Material and methods: Sixty-five patients with rheumatoid arthritis (46 women and 19 men; average age 50.83± 8.91 years) underwent an examination.Thirty-two patients (26 women and 6 men) participated in studyingmethotrexate pharmacokinetics.

Results and Discussion: The course of rheumatoid arthritis is accompanied by a significant increase of TNF-α (40.36±4.01 pg/ml), IL-1β (17.68±1.74 pg/ml), andIL- 6(8.39±0.46pg/ml) in the blood.Oral administration of methotrexate (MT) for patients with rheumatoid arthritis promotes persistent elimination of clinical disease symptoms and reduced production of proinflammatory cytokines:TNF-α drops by 2.08 times (p<0.05) compared to baseline, that of IL-1β and IL-6 – by 2.86 (p<0.05) and2.84times(p<0.05), correspondingly.Blood levels for TNF-α and IL-6 are consistent with clinical markers for rheumatoid arthritis, such as joint pain, joint swelling, and morning stiffness in extremities.Blood cytokine concentrations were not correlated with AUC, Cmax, and Tmax. There was an inverse correlation between the blood rates of TNF-α and the weekly dose of MT (r = -0.34, p<0.05) and II-6 and the weekly dose of MT (r = -0.32, p<0.05).

Conclusion: Rheumatoid arthritis is closely associated with increaseing of proinflammatory cytokine blood levels, which affects the clinical course of the disease.The dosage of methotrexate applied affects the blood concentrations of IL-6 and TNF-α.

Bangladesh Journal of Medical Science Vol. 21 No. 02 April’22 Page : 335-343

Downloads

Download data is not yet available.
Abstract
4
PDF
16

Downloads

Published

2022-02-25

How to Cite

Aringazina, R. ., Myasoutova, L. ., Babaskina, L. ., & Pashanova, O. . (2022). Correlation of pharmacokinetic dispositionof methotrexate and serum cytokine levels in rheumatoid arthritis patients. Bangladesh Journal of Medical Science, 21(2), 335–343. https://doi.org/10.3329/bjms.v21i2.58066

Issue

Vol. 21 No. 2 (2022)

Section

Original Articles

License

Copyright (c) 2022 Raisa Aringazina, Leysan Myasoutova, Liudmila Babaskina, Olga Pashanova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.